Advertisement

Topics

Herceptin (Trastuzumab)

00:34 EDT 22nd September 2017 | BioPortfolio

Herceptin is a targeted therapy approved for the treatment of people with certain HER2+ cancers. HER2+ cancer cells have more HER2 receptors (a particular protein found on the surface of cells) than normal cells. HER2+ cancer is considered aggressive because it grows and spreads quickly.

Who is Herceptin for?

Adjuvant Breast Cancer

Herceptin is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2+ and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have 1 high risk feature.

Metastatic Breast Cancer

Herceptin has 2 approved uses in metastatic breast cancer:

  • Herceptin in combination with the chemotherapy drug Taxol® (paclitaxel) is approved for the first line treatment of Human Epidermal growth factor Receptor 2-positive (HER2+) metastatic breast cancer
  • Herceptin alone is approved for the treatment of HER2+ breast cancer in patients who have received 1 or more chemotherapy courses for metastatic disease

Taxol is a registered trademark of Bristol-Myers Squibb Company.

Metastatic Gastric/GEJ Cancer

Herceptin is approved, in combination with chemotherapy (cisplatin and either capecitabine or 5-fluorouracil), for the treatment of HER2+ metastatic cancer of the stomach or gastroesophageal junction (where the esophagus meets the stomach) in patients who have not received prior treatment for their metastatic disease.

For further information open - http://www.herceptin.com/

Drug maker: Roche

Indication(s): HER2-positive breast cancer and HER2-positive metastatic gastric cancer

2012 sales: $6.397 billion (CHF 5.889 billion)4

 

Quick Search
Advertisement
 

review and buy Herceptin (Trastuzumab) market research data and corporate reports here